|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Phosphorylated IKKα(p45) is a nuclear active form of the IKKα kinase that is induced by the MAP kinases BRAF and TAK1 and promotes tumor growth independent of canonical NF-κB signaling.
|
31302002 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Stable knockdown of MAP3K7 attenuated tumor formation in a spheroid cell culture model and tumor xenograft mouse model.
|
31214512 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lower ERG expression in dural and intraparenchymal metastases suggests a possibility that ERG-negative tumors with loss of MAP3K7 may become resistant to standard therapies and diffusely metastasize.
|
30656528 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Additionally, endothelial TAK1 deletion reduces tumor burden.
|
30695692 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Noncanonical TGFβ Pathway Relieves the Blockade of IL1β/TGFβ-Mediated Crosstalk between Tumor and Stroma: TGFBR1 and TAK1 Inhibition in Colorectal Cancer.
|
30979739 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Synthesis and anti-tumor activity of imidazopyrazines as TAK1 inhibitors.
|
30576901 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Additionally, we determined that TAK1 deletion in tumor ECs resulted in blood vessel and hence tumor regression.
|
30639056 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As TAK1 is implicated in dual feedforward mechanisms to orchestrate the SASP development, pharmacologically targeting TAK1 deprives cancer cells of resistance acquired from treatment-damaged stromal cells in vitro and substantially promotes tumour regression in vivo.
|
29712904 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TAK1, a crucial mediator that upregulates NF-κB activation in response to cellular genotoxic stress, is required for tumor cell viability and survival.
|
28430599 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The activity of these inhibitors, in combination with the most commonly used chemotherapeutic drugs, has been tested in preclinical studies, proving the efficacy of TAK1 inhibition in reducing tumor growth and survival following chemotherapy administration.
|
29145973 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Downstream of SHP1 and SYK-dependent counterregulation of MyD88 tyrosine phosphorylation, we have demonstrated that the scaffolding function of receptor interacting protein kinase 1 (RIPK1) and tumor growth factor-β activated kinase 1 (TAK1)-mediating signaling were required to spur inflammatory disease.
|
28410990 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Accumulating evidence demonstrates that TAK1 plays a role in tumor initiation, progression, and metastasis as a tumor prompter or tumor suppressor.
|
24443058 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We conclude that EPEC enhances MIC-1 gene expression in the human intestinal cancer cells, which can be associated with enhanced tumor cell resistance to anchorage-dependent tumor cell death via enhanced TAK1 and RhoA GTPase.
|
23503457 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TGF-β-activated kinase-1 (TAK1) has been found to be over-expressed in a variety of solid malignancies and related to tumor growth.
|
23534745 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tissue microarrays constructed of 234 surgically resected T3N1-3M0 ESCC primary tumors were used for TAK1 evaluation by immunohistochemistry.
|
23272845 |
2013 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In summary, our study identifies MAP3K7 deletion as a prominent feature in ERG-negative prostate cancer with strong association to tumor aggressiveness.
|
23370768 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We report that its restored expression induces the death of genetically diverse melanoma lines and inhibits tumor growth through the activation of novel TAK1-dependent death pathways.
|
22898869 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor suppressor A20 protects against cardiac hypertrophy and fibrosis by blocking transforming growth factor-beta-activated kinase 1-dependent signaling.
|
20585109 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The orthotopic xenograft studies in SCID mice showed that suppression of TAK1 signaling by dn-TAK1 reduces tumor growth and formation of lung metastases.
|
17828308 |
2008 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Importantly, deletion of MAP3K7 was highly associated with higher-grade disease, occurring in 61% of tumors with Gleason score >or=8 compared with only 22% of tumors with Gleason score <or=7.
|
17785553 |
2007 |